文献速递核素与放射性配体治疗肿瘤 PET/CT

177Lu-DOTATATE治疗神经内分泌肿瘤疗程中的剂量学量变化

Dosimetric Quantities in Neuroendocrine Tumors over Treatment Cycles with 177Lu-DOTATATE.
PubMed 文献 · J Nucl Med · 2021-07-16

研究对41例1级或2级神经内分泌肿瘤患者行177Lu-DOTATATE治疗,采用混合平面-SPECT/CT对182个病灶进行剂量学评估,共880次吸收剂量测定。结果显示肿瘤吸收剂量随疗程平均下降,1级和2级分别每疗程下降6%和14%(P<0.05),2级有效半衰期更短(P<0.001)。

要点

  • 肿瘤每疗程吸收剂量范围为2至77 Gy
  • 1级和2级NET每疗程吸收剂量分别下降约6%和14%
  • 2级NET有效半衰期短于1级(P<0.001)

核心结论

  • 177Lu-DOTATATE治疗周期之间肿瘤吸收剂量、吸收剂量率和活性摄取随肿瘤体积下降而降低,2级NET尤为明显。
  • 有效半衰期变化较小,但2级NET低于1级NET,可能提示放射性纤维化发展并对未来治疗和剂量学方案设计有影响。

研究设计与样本

  • 数据来自41例1级(n=23)或2级(n=18)神经内分泌肿瘤患者,接受2至9个治疗周期。
  • 对182个独立病灶进行剂量学评估,共获得880次跨周期吸收剂量测定;采用混合平面-SPECT/CT成像,包括定量SPECT重建、基于体素的吸收剂量率计算、半自动图像分割和部分容积校正。
  • 使用线性混合效应模型分析肿瘤吸收剂量、第1天吸收剂量率和活性浓度、有效半衰期及肿瘤体积随周期的变化;小于8 cm3的肿瘤被排除分析。

主要发现

  • 肿瘤每周期吸收剂量范围为2至77 Gy。
  • 肿瘤吸收剂量平均随周期下降,1级和2级NET分别每周期显著下降6%和14%(P<0.05)。
  • 第1天吸收剂量率和活性浓度下降幅度相似;有效半衰期变化较小但2级短于1级(P<0.001)。
  • 2级NET肿瘤体积减小,1级有类似趋势。

临床怎么用

  • 在177Lu-DOTATATE治疗中应关注肿瘤吸收剂量随疗程下降的趋势,尤其对2级NET可能需要考虑调整给药方案。
  • 剂量学评估可纳入有效半衰期和肿瘤体积变化,以辅助判断辐射诱导纤维化等生物学效应。

局限性

  • 小于8 cm3的肿瘤被排除分析,结论不适用于小病灶。
  • 样本量有限(41例患者、182个病灶),且为观察性剂量学分析,未评估临床结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Tumor dosimetry was performed for 177Lu-DOTATATE with the aims of better understanding the range and variation of the tumor-absorbed doses (ADs), how different dosimetric quantities evolve over the treatment cycles, and whether this evolution differs depending on the tumor grade. Such information is important for radiobiologic interpretation and may inform the design of alternative administration schemes. Methods: The data came from 41 patients with neuroendocrine tumors (NETs) of grade 1 (n = 23) or 2 (n = 18) who had received between 2 and 9 treatment cycles. Dosimetry was performed for 182 individual lesions, giving a total of 880 individual AD assessments across all cycles. Hybrid planar-SPECT/CT imaging was used, including quantitative SPECT reconstruction, voxel-based absorbed-dose-rate calculation, semiautomatic image segmentation, and partial-volume correction. Linear mixed-effect models were used to analyze changes in tumor ADs over cycles, absorbed-dose rates and activity concentrations on day 1, effective half-times, and tumor volumes. Tumors smaller than 8 cm3 were excluded from analyses. Results: Tumor ADs ranged between 2 and 77 Gy per cycle. On average, the AD decreased over the cycles, with significantly different rates (P < 0.05) of 6% and 14% per cycle for grade 1 and 2 NETs, respectively. The absorbed-dose rates and activity concentrations on day 1 decreased by similar amounts. The effective half-times were less variable but shorter for grade 2 than for grade 1 (P < 0.001). For grade 2 NETs, the tumor volumes decreased, with a similar tendency in grade 1. Conclusion: The tumor AD, absorbed-dose rate, and activity uptake decrease, in parallel with tumor volumes, between 177Lu-DOTATATE treatment cycles, particularly for grade 2 NETs. The effective half-times vary less but are lower for grade 2 than grade 1 NETs. These results may indicate the development of radiation-induced fibrosis and could have implications for the design of future treatment and dosimetry protocols.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Roth D, Gustafsson J, Warfvinge CF, et al. Dosimetric Quantities in Neuroendocrine Tumors over Treatment Cycles with 177Lu-DOTATATE. J Nucl Med. 2021. PMID: 34272319. doi:10.2967/jnumed.121.262069

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。